| 引用本文： |
-
胡艺凡,于 倩,刘芝翠,等.糠酸莫米松和他克莫司序贯疗法治疗面部化妆品接触性皮炎的临床研究[J].同济大学学报（医学版）,2019,40(4):474-478. [点击复制]
- HU Yi-fan,YU Qian,LIU Zhi-cui,et al.Mometasonefuroate cream combined with tacrolimus ointment in treatment of facial cosmetic contact dermatitis[J].同济大学学报（医学版）,2019,40(4):474-478. [点击复制]
|
|
| 摘要: |
| 目的 观察糠酸莫米松和他克莫司序贯疗法治疗面部化妆品接触性皮炎的有效性和安全性。方法 随机将160例面部化妆品接触性皮炎患者分为治疗组和对照组。治疗组先给予0.1%糠酸莫米松乳膏治疗1周，然后给予0.1%他克莫司软膏维持治疗3周；对照组给予0.1%糠酸莫米松乳膏治疗1周，然后给予单乳膏维持治疗3周，总疗程为4周。在治疗第1、4、8、12周随访，比较两组患者治疗前后愈显率、症状积分、复发率和不良反应发生情况。结果 治疗1周后，治疗组愈显率为92.68%，对照组愈显率为92.30%。两组疗效差异无统计学意义（P>0.05）。第4、8、12周随访，在临床治愈患者中，治疗组患者复发率（5.97%）明显低于对照组（18.75%），两组复发率差异有统计学意义（P<0.05）。两组患者治疗后均无色素沉着、毛细血管扩张或皮肤萎缩等不良反应。结论 糠酸莫米松和他克莫司序贯疗法治疗面部化妆品接触性皮炎疗效好，复发率低，患者依从性好，可作为治疗面部化妆品接触性皮炎的选择。 |
| 关键词: 接触性皮炎 化妆品 糠酸莫米松 他克莫司软膏 序贯治疗 |
| DOI：10.16118/j.1008-0392.2019.04.014 |
| 投稿时间：2019-04-13 |
| 基金项目:国家自然科学基金（81872522，81673050）；上海市科学技术委员会项目（18140901800）；上海卫生计生系统优秀学科带头人计划基金（2018BR30） |
|
| Mometasonefuroate cream combined with tacrolimus ointment in treatment of facial cosmetic contact dermatitis |
| HU Yi-fan,YU Qian,LIU Zhi-cui,GONG Yu,WANG Yao,SHI Yu-ling |
| (Dept. of Dermatology, Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China) |
| Abstract: |
| Objective To assess the clinical efficacy and safety of mometasonefuroate cream combined with tacrolimus ointment in treatment of facial cosmetic contact dermatitis. Methods One hundred and sixty patients with facial cosmetic contact dermatitis were randomly divided into two groups: 82 patients in study group were treated with 0.1% mometasonefuroate cream for the first week then 0.1% tacrolimus ointment for the next three weeks, while 78 patients in control group were treated with 0.1% mometasonefuroate cream for the first week then moisturizer for the next three weeks. The markedly effective rate, symptom score, recurrence rate and adverse reactions of the two groups were compared at 1st, 4th, 8th and 12th weeks. Results After the first week of treatment, the markedly effective rate of study group and control group were 92.68% and 92.31%, respectively (P>0.05). After 4, 8 and 12 weeks follow-up, the recurrence rate of the patients in the study group was significantly lower than that in control group (5.97% vs 18.75%, P<0.05). No adverse effects, including pigmentation, telangiectasia, or atrophy of skin were found in the two groups. Conclusion Mometasonefuroate cream combined with tacrolimus ointment is effective and safe in the treatment of facial cosmetic contact dermatitis. |
| Key words: contact dermatitis cosmetic mometasonefuroate tacrolimus sequence therapy |
